No Data
Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients With Lower Plasma P-tau217 Correlated With Improvements in Key Indicators of Alzheimer's Disease Biology
Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Express News | Cognition Therapeutics’ Analysis Correlates Biomarker Changes With Cognitive Benefit in Alzheimer’s Population
Cognition Therapeutics' Analysis Correlates Biomarker Changes With Cognitive Benefit in Alzheimer's Population
Cognition Therapeutics | 10-Q: Q3 2024 Earnings Report
Cognition Therapeutics | 8-K: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
No Data
No Data
1.00 incoming lmao 
where did you get your math from Elementary you're just coming up with the Magic 
1.00 lol 
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}